Full-Time

Associate Director

Alliance Management

Confirmed live in the last 24 hours

Verve Therapeutics

Verve Therapeutics

201-500 employees

Develops gene editing therapies for cardiovascular disease

Biotechnology
Healthcare

Senior, Expert

No H1B Sponsorship

Boston, MA, USA

Hybrid role requiring 3 days in the Boston office.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in sciences or related field required; MBA, PhD preferred.
  • Minimum of 9 years of experience in pharmaceutical/biotechnology industry, including 5+ years in project management and/or alliance management.
  • Early-stage drug development knowledge.
  • Ability to effectively plan, prioritize and coordinate multiple tasks and adjust to changing priorities to deliver results to tight deadlines.
  • Must be comfortable speaking and presenting to diverse audiences, including leadership and external stakeholders.
  • Ability to think both strategically and tactically, and effectively present recommendations to senior leaders and key stakeholders.
  • Attention to detail and ability to prioritize and influence others.
  • Excellent interpersonal skills.
  • Demonstrated competence in written and verbal communication.
  • Must be proficient in MS Word, Excel and PowerPoint.
Responsibilities
  • Assist in overseeing the overall portfolio of strategic partnerships, effectively partnering with cross functional team members to ensure key corporate strategies and goals are aligned and achieved.
  • Facilitate cross-functional team member preparations for joint committee meetings and presentations, ensuring project plans and timelines are met and goals and obligations are met.
  • Regularly communicate with partner alliance management counterparts and other key partner stakeholders engaging on the various issues and opportunities arising from the collaboration.
  • Liaise with Legal, Finance, Business Development, and cross-functional teams to ensure that key contract terms, including roles & responsibilities, milestones, financial transactions, progress reports, etc. are executed appropriately.
  • Develop agendas, facilitate the key discussion points and decisions at partner meetings.
  • Conduct meetings with partners to steer strategy, alliance operations, and identify new value-creating opportunities from collaborations.
  • Proactively anticipate or identify issues, whether internal or from partner interactions, and collaborate with team leadership and relevant stakeholders to develop strategies and drive resolutions.
  • Keep team informed of key issues, milestones and changes.
  • Build and maintain strong relationships with various partner personnel.
  • Other duties as assigned.

Verve Therapeutics focuses on developing gene editing therapies to treat cardiovascular disease. Their approach involves creating single-course treatments that aim to provide lasting solutions rather than ongoing management. The company targets specific genes, such as PCSK9 and ANGPTL3, which are known to influence blood lipid levels. This targeted gene editing could potentially offer patients a more effective and permanent option for managing their cardiovascular health. Unlike many traditional therapies that require continuous use, Verve's products are designed to be one-time treatments. The goal of Verve Therapeutics is to transform cardiovascular care by providing curative options for patients, ultimately improving their quality of life.

Company Stage

N/A

Total Funding

$353.6M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

6%

1 year growth

8%

2 year growth

34%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant financial backing, including a $63 million Series A2 financing and $60 million from Eli Lilly, positions Verve for robust R&D and clinical trial activities.
  • The potential for a 'one-and-done' treatment for cardiovascular diseases could revolutionize the field and offer a high-impact, life-saving solution.
  • Early-stage success and strategic partnerships could lead to lucrative licensing deals and further investment opportunities.

What critics are saying

  • The clinical-stage nature of Verve's therapies means they are still years away from potential market approval, posing a long-term risk.
  • The recent stock price drop following a public offering indicates market volatility and potential investor uncertainty.

What makes Verve Therapeutics unique

  • Verve Therapeutics focuses on gene-editing therapies specifically for cardiovascular diseases, setting it apart from other CRISPR-based companies that target a broader range of conditions.
  • Their 'one-and-done' gene-editing approach aims to provide a single, curative treatment, which is a significant advantage over traditional, ongoing therapies.
  • Partnerships with major pharmaceutical companies like Eli Lilly enhance their credibility and provide substantial financial and research support.

Help us improve and share your feedback! Did you find this helpful?